Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Uromonitor: Clinical Validation and Performance Assessment of a Urinary Biomarker Within the Surveillance of Patients With Nonmuscle-Invasive Bladder Cancer.

The Journal of urology - 1 Mar 2025

Ramos Pedro, Brás João P, Dias Carolina, Bessa-Gonçalves Mafalda, Botelho Francisco, Silva João, Silva Carlos, Pacheco-Figueiredo Luís

Abstract excerpt

PURPOSE: Alternative, noninvasive, cost-effective methods to complement or serve as substitutes to current standard-of-care (SOC) procedures in nonmuscle-invasive bladder cancer (NMIBC) follow-up are needed. Uromonitor is a urine biomarker test detecting bladder cancer recurrence through the screening of TERT, FGFR3, and KRAS hotspot mutations. The aim of this study was to assess Uromonitor performance by...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Neoplasm Invasiveness
Share to Neoplasm Recurrence, Local

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Predictive Value of Tests

Share to Proto-Oncogene Proteins p21(ras)

Share to Receptor, Fibroblast Growth Factor, Type 3

Share to Sensitivity and Specificity

Share to Telomerase

Share to Urinary Bladder Neoplasms

Source

Identifiers

PMID: 39561374
DOI: 10.1097/JU.0000000000004335

Genes

FGFR3
KRAS
TERT

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 2 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Uromonitor: Clinical Validation and Performance Assessment of a Urinary Biomarker Within the Surveillance of Patients With Nonmuscle-Invasive Bladder Cancer.PMID 39561374Read ↗

Uromonitor®: Clinical Validation and Performance Assessment of a Urinary Biomarker for Recurrence Surveillance in Non-Muscle Invasive Bladder Cancer PatientsSemantic proximity Read ↗

Uromonitor <sup>®</sup> as a novel sensitive and specific urine-based test for recurrence surveillance of patients with non-muscle invasive bladder cancerSemantic proximity Read ↗

Improving diagnostic molecular tests to monitor urothelial carcinoma recurrence.Semantic proximity Read ↗

Performance Characteristics of a Multigene Urine Biomarker Test for Monitoring for Recurrent Urothelial Carcinoma in a Multicenter StudySemantic proximity Read ↗

Real-world performance of Uromonitor® in urothelial bladder cancer detection: a multicentric trial.Semantic proximity Read ↗

A urinary assay for mutation and methylation biomarkers in the diagnosis and recurrence prediction of non-muscle invasive bladder cancer patients.Semantic proximity Read ↗

Diagnostic Test Accuracy of Commercially Available Tests for The Recurrence of Bladder Cancer: A Systematic Review and Meta-AnalysisSemantic proximity Read ↗

Urinary Biomarkers in Urothelial Carcinoma: Expanded Con-temporary Evidence for Diagnosis, Surveillance, Risk Stratification, and Cystoscopy-Sparing Clinical PathwaysSemantic proximity Read ↗

Urinary Biomarkers in Bladder Cancer: FDA-Approved Tests and Emerging Tools for Diagnosis and SurveillanceSemantic proximity Read ↗

Diagnostic performance of Uromonitor and TERTpm ddPCR urine tests for the non-invasive detection of bladder cancer.Semantic proximity Read ↗

Digital PCR-Based Uromonitor for Molecular Detection of Bladder Cancer: A Multicenter Validation Study Comparing Quantitative PCR and Urine Cytology.Semantic proximity Read ↗

Distinct longitudinal patterns of urine tumor DNA in patients undergoing surveillance for bladder cancerSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.